Recent Updates
Recently added Catalysts
SNDX Positive Sentiment Score: 75/100

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Friday, September 5, 2025 1 min read
Key Takeaway: Syndax Pharmaceuticals announced the granting of inducement awards for the purchase of 167,400 shares of common stock to 11 new employees under its 2023 Inducement Plan. The stock options will vest over a period of four years, contingent upon the continued employment of these individuals. The company highlights its commitment to cancer care through its pipeline, which includes FDA-approved drugs such as Revuforj® and Niktimvo™. This move is seen as a strategic effort to bolster its workforce as it advances its clinical trials and treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Syndax granted stock options to 11 new employees, indicating growth and expansion.
  • The company has FDA-approved therapies in its pipeline, showcasing its innovative approach to cancer care.

Full Press Release Details

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Pharmaceuticals, Inc.

Frequently Asked Questions

What inducement awards did Syndax grant recently?

Syndax granted inducement awards for 167,400 shares of common stock to 11 new employees.

How will the stock options vest for new employees?

The stock options will vest over four years, with 25% vesting after one year.

What are Syndax's key products?

Syndax's key products include Revuforj® and Niktimvo™, both FDA-approved.

What is Syndax's focus as a biopharmaceutical company?

Syndax focuses on advancing innovative therapies and unlocking its pipeline's potential.

Where can I find more information about Syndax?

More information is available at www.syndax.com and on their social media profiles.

Tags: SNDX Viatris Investor Conferences Healthcare cancer therapies FDA-approved stock options inducement plan
Last updated: Sep 5, 2025